SBV Journal of Basic, Clinical and Applied Health Science

Register      Login

VOLUME 2 , ISSUE 2 ( April-June, 2019 ) > List of Articles

Original Article

Status of ER, PR, HER-2 and E-cadherin Expression in 86 Female Breast Cancer Patients from Bangladesh

Tania Gaffar, Muhammad N Baqui, Sabina Yasmin, Sharmin Rozhana, Nur-E-Jannatul Ferdous

Keywords : Breast cancer, E-cadherin, Estrogen receptors, Human epidermal growth factor receptor 2, Progesterone receptors

Citation Information : Gaffar T, Baqui MN, Yasmin S, Rozhana S, Ferdous N. Status of ER, PR, HER-2 and E-cadherin Expression in 86 Female Breast Cancer Patients from Bangladesh. 2019; 2 (2):61-64.

DOI: 10.5005/jp-journals-10082-02203

License: CC BY-NC 4.0

Published Online: 01-11-2019

Copyright Statement:  Copyright © 2019; The Author(s).


Background and objectives: Breast carcinoma of female is a leading cause of morbidity and mortality. Till date, a lot of studies have been carried out to find the accurate prognostic parameters of breast carcinoma to facilitate its treatment. In Asian population frequency of reactivity of some of these parameters like estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER-2) and E-cadherin receptor differs from the western population. As no more data are available on Bangladeshi population, this study was designed to find out the status of these receptors for this specific ethnic group. Materials and methods: Total 86 histopathologically confirmed samples of breast carcinoma were included in this study. Histologically, they were divided into lobular and nonlobular category. Immunostain was done for ER, PR, HER-2 and E-cadherin receptor study. Statistical analysis was done to find out the association of these receptors with histological classification and grade. Results: The mean age of the patients was 45.6 ± 10.7 years. Among histological subtype, total 9 (10.5%) found to be of lobular category and 77 (89.5%) were nonlobular type. Out of 86 patients, almost two third (61.6%) of patients were ER positive and 54.7% were PR positive. On the other hand 24 (27.9%) patients showed HER-2 overexpression and 79.1% patient showed E-cadherin positivity. About 64 (83.1%) nonlobular carcinoma was positive for E-cadherin. Only E-cadherin receptor showed significant association with histological classification. Conclusion: It has been found that Bangladeshi population has lower rate of ER positivity when compared with the Western population and there is significant association between the histological type of breast carcinoma and E-cadherin receptor positivity.

  1. Chiedozi LC, El-Hag IA, Kollur SM. Breast diseases in the Northern region of Saudi Arabia. Saudi Med J 2003;24:623–627.
  2. El Hag IA, Katchabeswaran R, Chiedozi LC, Kollur SM. Pattern and incidence of cancer in Northern Saudi Arabia. Saudi Med J 2002;23:1210–1213.
  3. WHO, Cancer country profiles 2014,, accessed on 8 February 2019.
  4. Hossain MS, Ferdous S, Karim-Kos HE. Breast cancer in South Asia: A Bangladeshi perspective. Cancer Epidemiol 2014;38:465–470. DOI: 10.1016/j.canep.2014.08.004.
  5. Paul TK, Banu PA, Alam MSS, Sharif R, Rukhsana N, Monower MM. The overview of cancer patients attending in a specialized hospital: a cross sectional study. Bangladesh Med Res Counc Bull 2016;41:95–100. DOI: 10.3329/bmrcb.v41i2.29990.
  6. Chand P, Garg A, Singla V, Rani N. Evaluation of Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use. Niger J Surg 2018;24:100–106. DOI: 10.4103/njs.NJS_2_18.
  7. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002;29:231–245. DOI: 10.1053/sonc.2002.32899.
  8. Patnayak R, Jena A, Rukmangadha N, Chowhan AK, Sambasivaiah K, Phaneendra BV, et al. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: a tertiary care center experience. Indian J Med Paediatr Oncol 2015;36:117–122. DOI: 10.4103/0971-5851.158844.
  9. Jensen EV. Steroid receptors in breast cancer: historical perspective. Cancer 1980;46:2759–2761. DOI: 10.1002/1097- 0142(19801215)46:12+<2759::AID-CNCR2820461402>3.0.CO;2-7.
  10. Senevirathne MBS, Beneragama DH. Assessment of the impact of the concentration of formalin on receptor studies in surgical specimens of breast carcinoma: a pilot study. J Diagn Pathol 2014;9:24. DOI: 10.4038/jdp.v9i1.7651.
  11. Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev 2011;12:625–629.
  12. Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem 1990;59:237–252. DOI: 10.1146/
  13. Berx G, Staes K, van Hengel J, Molemans F, Bussemakers MJ, Van Bokhoven A, et al. Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 1995;26: 281–289. DOI: 10.1016/0888-7543(95)80212-5.
  14. Bracke ME, Van Roy FM, Mareel MM. The E-cadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 1996;213: 123–161.
  15. Howard EM, Lau SK, Lyles RH, Birdsong GG, Umbreit JN, Kochhar R. Expression of e-cadherin in high-risk breast cancer. J Cancer Res Clin Oncol 2005;131:14–18. DOI: 10.1007/s00432-004-0618-z.
  16. Younis LK, El Sakka H, Haque I. The Prognostic Value of E-cadherin Expression in Breast Cancer. Int J Health Sci 2007;1:43–51.
  17. Fattahi AS, Tavassoli A, Rohbakhshfar O, Sadeghi R, Abdollahi A, Forghani MN. Can methylene blue dye be used as an alternative to patent blue dye to find the sentinel lymph node in breast cancer surgery? J Res Med Sci 2014;19:918–922.
  18. Özdemir A, Mayir B, Demirbakan K, Oygür N. Efficacy of Methylene Blue in Sentinel Lymph Node Biopsy for Early Breast Cancer. J Breast Health 2014;10:88–91. DOI: 10.5152/tjbh.2014.1914.
  19. ElMoneim HMA, Zaghloul NM. Expression of E-cadherin, N-cadherin and snail and their correlation with clinicopathological variants: an immunohistochemical study of 132 invasive ductal breast carcinomas in Egypt. Clinics (Sao Paulo) 2011;66:1765–1771.
  20. Mandal A. Hormone receptors in breast carcinoma. Indian J Pathol Microbiol 1995;38:109–188.
  21. Kaul R, Sharma J, Minhas SS, Mardi K. Hormone Receptor Status of Breast Cancer in the Himalayan Region of Northern India. Indian J Surg 2011;73:9–12. DOI: 10.1007/s12262-010-0121-5.
  22. Shukla A, Singh P, Shukla A, Mehrotra PK, Arshad F, Jain P. Study of correlation of ER, PR, HER-2 receptor status in breast cancer at a single tertiary care hospital with emphasis on clinical utility of PR receptor. Int J Community Med Public Health 2018;5:4853–4857. DOI: 10.18203/2394-6040.ijcmph20184584.
  23. Wong H, Lau S, Cheung P, Wong TT, Parker A, Yau T, et al. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy. BMC Cancer 2014;14:826. DOI: 10.1186/1471-2407-14-826.
  24. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003;5:217–222. DOI: 10.1186/bcr651.
  25. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001;115:85–98. DOI: 10.1309/FDHX-L92R-BATQ-2GE0.
  26. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 1993;142: 987–993.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.